Regulatory Ahead of ASCO data drop, AZ gets key Imfinzi approval PharmaphorumAstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease.OncologyRead full story pharminent May 29, 2026 (Last updated: May 29, 2026) Pharmaphorum AstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Medicare Advantage Out-of-Pocket Limits: Variation and TrendsNext: GSK’s Nucala secures NICE COPD endorsement Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
